A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS
| Registry | NCT05035212, acronym RENOIR |
|---|---|
| Status | Active not recruiting |
| Phase | Phase 3 |
| Study type | Interventional; randomized, parallel, masking: triple, prevention |
| Enrollment | 38861 (Actual) |
| Sponsor | Pfizer (Industry) |
| Conditions | Lower Respiratory Tract Illness |
| Interventions | RSVpreF, Placebo (Biological) |
| Dates | start 2021-08-31, primary completion 2027-01-18 (estimated), completion 2027-01-18 (estimated), first posted 2021-09-05, last updated 2026-01-28 |
| Locations | 263 sites in United States, Argentina, Canada, Finland, Japan, Netherlands, South Africa |
Related Papers Related Patents Related Grants Related Experts
All trials for Lower Respiratory Tract Illness All trials of RSVpreF All trials of Placebo
Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults:
* At a dose of 120µg.
* In adults 60 years of age and older.
* The duration of the study for each participant will be up to approximately 24 months.
* The study will be conducted in the United States, Canada, Netherlands, Finland, Argentina, Japan and South Africa.
Substudy A: This study is an extension of the efficacy study and was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of approximately 2 years:
* At a dose of 120µg (as studied in the Phase 3 Efficacy Study)
* Blood samples will be collected for antibody testing.
* The duration of the study for each participant will be up to approximately 18 months.
* The study will be conducted in the United States and Argentina.
Substudy B: This study was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of approximately 1 year:
* At a dose of 120µg (as studied in the Phase 3 Efficacy Study)
* Blood samples will be collected for antibody testing.
* The duration of the study for each participant will be up to approximately 18 months.
* The study will be conducted in Argentina.
Substudy C: This study was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of either 3 or 4 years:
* At a dose of 120µg (as studied in the Phase 3 Efficacy Study)
* Participants will receive either placebo or a second dose of RSVpreF approximately 3 or 4 years after receiving the initial dose of RSVpreF in the main efficacy study.
* Blood samples will be collected for antibody testing.
* The duration of the study for each participant will be up to approximately 24 months.
* The study will be conducted in the United States and Canada.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Efficacy Study: RSVpreF vaccine | Experimental | Biological: RSVpreF | RSVpreF |
| Efficacy Study: Placebo dose | Placebo comparator | Biological: Placebo | Placebo |
| SSA: Vaccination of RSVpreF recipients with RSVpreF (Year 2 revaccination) | Experimental | Biological: RSVpreF | Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSA will receive RSVpreF in SSA. |
| SSA: Vaccination of RSVpreF recipients with Placebo | Placebo comparator | Biological: Placebo | Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSA will receive Placebo in SSA. |
| SSB: Vaccination of RSVpreF recipients with RSVpreF (Year 1 revaccination) | Experimental | Biological: RSVpreF | Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSB will receive RSVpreF in SSB. |
| SSB: Vaccination of RSVpreF recipients with Placebo | Placebo comparator | Biological: Placebo | Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSB will receive Placebo in SSB. |
| SSC: Vaccination of RSVpreF recipients with RSVpreF (Year 3 revaccination) | Experimental | Biological: RSVpreF | Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSC will receive RSVpreF at the Year 3 vaccination followed by placebo at the Year 4 vaccination in SSC. |
| SSC: Vaccination of RSVpreF recipients with RSVpreF (Year 4 revaccination) | Experimental | Biological: RSVpreF | Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSC will receive placebo at the Year 3 vaccination followed by RSVpreF at the Year 4 vaccination in SSC. |
| SSC: Vaccination of RSVpreF recipients with Placebo | Placebo comparator | Biological: Placebo | Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSC will receive placebo at both the Year 3 and Year 4 vaccination in SSC. |
Sex: All, ages: 60 Years to any, accepts healthy volunteers
Efficacy Study Inclusion Criteria: * Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures, including collection of nasal swabs by themselves and by study staff when indicated. * Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for participants with known stable infection with HIV, HCV, or HBV can be found in the protocol. * Adults who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living. * Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. * Male or female participants ≥60 years of age. * Male participants able to father children must agree to use a highly effective method of contraception from the time of informed consent through at least 28 days after study intervention administration. * Female participants must not be of childbearing potential. Exclusion Criteria: * Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine. * Serious chronic disorder including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study. * Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. * Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-months follow-up visit (Visit 3). Note: This criterion does not apply to participants who are participating in a follow-up period for another study involving a study intervention that is an investigational drug or vaccine, if receipt of the last dose was at least 6 months prior to consenting for this study and there is no further dosing anticipated from the previous study during the participant's participation in this study - Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted. Note: Participants with COPD or asthma can be enrolled if chronic corticosteroids do not exceed a dose equivalent to 10 mg/day of prednisone. * Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration. * Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation. * Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. Substudy A Inclusion Criteria: * Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures, including collection of nasal swabs by themselves and by study staff when indicated. * Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for participants with known stable infection with HIV, HCV, or HBV can be found in the protocol. * Adults who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living. * Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. * Male or female participants ≥60 years of age. * Male participants able to father children must agree to use a highly effective method of contraception from the time of informed consent through at least 28 days after study intervention administration. * Female participants must not be of childbearing potential. * Participants who received RSVpreF in the efficacy study. * Participants who have a Visit 2 serology sample available for testing from the efficacy study, completed the end-of-Season 2 visit (Visit 5), and did not meet exclusion criteria throughout the efficacy study duration. Exclusion Criteria: * Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine. * Serious chronic disorder including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study. * Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. * Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-months follow-up visit (Visit 103). Note: This criterion does not apply to participants who are participating in a follow-up period for another study involving a study intervention that is an investigational drug or vaccine, if receipt of the last dose was at least 6 months prior to consenting for this study and there is no further dosing anticipated from the previous study during the participant's participation in this study \- Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted. Note: Participants with COPD or asthma can be enrolled if chronic corticosteroids do not exceed a dose equivalent to 10 mg/day of prednisone. * Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration. * Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation. Note: This criterion does not include the receipt of RSVpreF in the efficacy study. Per inclusion criterion #6, receipt of RSVpreF in the efficacy study is required to participate in Substudy A. * Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. * Participant was confirmed by the sponsor to have previously received the study intervention more than once. Substudy B Inclusion Criteria: * Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures, including collection of nasal swabs by themselves and by study staff when indicated. * Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for participants with known stable infection with HIV, HCV, or HBV can be found in the protocol. * Adults who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living. * Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. * Male or female participants ≥60 years of age. * Male participants able to father children must agree to use a highly effective method of contraception from the time of informed consent through at least 28 days after study intervention administration. * Female participants must not be of childbearing potential. 6. Participants who received RSVpreF in the efficacy study. * Participants who received RSVpreF in the efficacy study. * Participants who have a Visit 2 serology sample available for testing from the efficacy study and did not meet exclusion criteria through Visit 4 of the efficacy study. Exclusion Criteria: * Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine. * Serious chronic disorder including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study. * Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. * Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-months follow-up visit (Visit 203). Note: This criterion does not apply to participants who are participating in a follow-up period for another study involving a study intervention that is an investigational drug or vaccine, if receipt of the last dose was at least 6 months prior to consenting for this study and there is no further dosing anticipated from the previous study during the participant's participation in this study - Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted. Note: Participants with COPD or asthma can be enrolled if chronic corticosteroids do not exceed a dose equivalent to 10 mg/day of prednisone. * Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration. * Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation. Note: This criterion does not include the receipt of RSVpreF in the efficacy study. Per inclusion criterion #6, receipt of RSVpreF in the efficacy study is required to participate in Substudy B. * Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. * Participant was confirmed by the sponsor to have previously received the study intervention more than once. * Participants who completed Vaccination 1 from the efficacy study less than 9 months or greater than 15 months prior to revaccination. Substudy C Inclusion Criteria: * Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures, when indicated. * Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for participants with known stable infection with HIV, HCV, or HBV can be found in the protocol. * Adults who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living. * Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. * Male or female participants ≥60 years of age. * Participants who received RSVpreF in the efficacy study. * Participants who have a Visit 2 serology sample available for testing from the efficacy study, completed the end-of-Season 2 visit (Visit 5), and did not meet exclusion criteria throughout the efficacy study duration. Exclusion Criteria: * Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine. * Serious chronic disorder including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study. * Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. * Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-months follow-up visit (Visit 303 or Visit 306). Note: This criterion does not apply to participants who are participating in a follow-up period for another study involving a study intervention that is an investigational drug or vaccine, if receipt of the last dose was at least 6 months prior to consenting for this study and there is no further dosing anticipated from the previous study during the participant's participation in this study \- Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted. Note: Participants with COPD or asthma can be enrolled if chronic corticosteroids do not exceed a dose equivalent to 10 mg/day of prednisone. * Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration. * Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation. Note: This criterion does not include the receipt of RSVpreF in the efficacy study. Per inclusion criterion #6, receipt of RSVpreF in the efficacy study is required to participate in Substudy C. * Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. * Participant was confirmed by the sponsor to have previously received the study intervention more than once. * Prior history of any subtype of Guillain-Barré syndrome of any etiology. * Current or prior participation in Substudy A or Substudy B. * Participants who completed Vaccination 1 from the efficacy study less than 32 months or greater than 40 months prior to revaccination.
| Facility | City | Country | Status |
|---|---|---|---|
| St. Vincent's Birmingham (Pharmacy) | Birmingham, Alabama | United States | |
| St. Vincent's Birmingham | Birmingham, Alabama | United States | |
| Medical Affiliated Research Center | Huntsville, Alabama | United States | |
| Lenzmeier Family Medicine / Avacare | Glendale, Arizona | United States | |
| Phoenix Clinical LLC | Phoenix, Arizona | United States | |
| HOPE Research Institute | Phoenix, Arizona | United States | |
| The Pain Center of Arizona | Phoenix, Arizona | United States | |
| HOPE Research Institute | Phoenix, Arizona | United States | |
| Cognitive Clinical Trials, LLC | Phoenix, Arizona | United States | |
| Headlands Research - Scottsdale | Scottsdale, Arizona | United States | |
| Alliance for Multispecialty Research, LLC | Tempe, Arizona | United States | |
| HOPE Research Institute | Tempe, Arizona | United States | |
| Noble Clinical Research | Tucson, Arizona | United States | |
| The Institute for Liver Health dba Arizona Clinical Trials | Tucson, Arizona | United States | |
| Hope Clinical Research | Canoga Park, California | United States | |
| eStudySite | Chula Vista, California | United States | |
| Benchmark Research | Colton, California | United States | |
| West Coast Research | Dublin, California | United States | |
| Marvel Clinical Research 002, LLC | Huntington Beach, California | United States | |
| Chemidox Clinical Trials | Lancaster, California | United States | |
| Ark Clinical Research | Long Beach, California | United States | |
| Downtown L.A. Research Center, Inc. | Los Angeles, California | United States | |
| Velocity Clinical Research, North Hollywood | North Hollywood, California | United States | |
| Clinica mi Salud by Focil Med | Oxnard, California | United States | |
| De Silva Medical Inc | Palmdale, California | United States | |
| Empire Clinical Research | Pomona, California | United States | |
| Paradigm Clinical Research Center | Redding, California | United States | |
| Artemis Institute for Clinical Research | Riverside, California | United States | |
| Benchmark Research | Sacramento, California | United States | |
| Artemis Institute for Clinical Research | San Diego, California | United States | |
| California Research Foundation | San Diego, California | United States | |
| Diablo Clinical Research, Inc. | Walnut Creek, California | United States | |
| Lynn Institute of Denver | Aurora, Colorado | United States | |
| Tekton Research LLC | Longmont, Colorado | United States | |
| Clinical Research Consulting | Milford, Connecticut | United States | |
| Stamford Therapeutics Consortium | Stamford, Connecticut | United States | |
| JEM Research Institute | Atlantis, Florida | United States | |
| IDEAL Clinical Research | Aventura, Florida | United States | |
| Innovative Research of West Florida | Clearwater, Florida | United States | |
| Invictus Clinical Research Group, LLC | Coconut Creek, Florida | United States | |
| Nature Coast Clinical Research | Crystal River, Florida | United States | |
| Universal Axon Clinical Research, LLC (Administrative) | Doral, Florida | United States | |
| Indago Research & Health Center, Inc | Hialeah, Florida | United States | |
| Doral Medical Research, LLC | Hialeah, Florida | United States | |
| M3 Wake Research - Lake City | Lake City, Florida | United States | |
| Optimus U Corporation | Miami, Florida | United States | |
| Advance Medical Research Center | Miami, Florida | United States | |
| Flourish Research - Miami, LLC | Miami, Florida | United States | |
| Optimus U Corporation | Miami, Florida | United States | |
| Next Phase Research Alliance | Miami, Florida | United States | |
| New Horizon Research Center | Miami, Florida | United States | |
| De La Cruz Research Center, LLC | Miami, Florida | United States | |
| Global Health Research Center, Inc. | Miami Lakes, Florida | United States | |
| Headlands Research Orlando | Orlando, Florida | United States | |
| Pines Care Research Center, LLC | Pembroke Pines, Florida | United States | |
| IDEAL Clinical Research | Pembroke Pines, Florida | United States | |
| DBC Research USA | Pembroke Pines, Florida | United States | |
| Headlands Research Sarasota | Sarasota, Florida | United States | |
| Precision Clinical Research | Sunrise, Florida | United States | |
| Clinical Site Partners, LLC dba Flourish Research | Winter Park, Florida | United States | |
| Conquest Research | Winter Park, Florida | United States | |
| Javara - Privia Medical Group Georgia - Albany | Albany, Georgia | United States | |
| Coastal Heritage Clinical Research | Hinesville, Georgia | United States | |
| Javara - Privia Medical Group Georgia - Savannah | Savannah, Georgia | United States | |
| Velocity Clinical Research, Savannah | Savannah, Georgia | United States | |
| Clinical Research Atlanta | Stockbridge, Georgia | United States | |
| Javara Inc. | Thomasville, Georgia | United States | |
| Snake River Research, PLLC | Idaho Falls, Idaho | United States | |
| Solaris Clinical Research | Meridian, Idaho | United States | |
| Great Lakes Clinical Trials, LLC dba Flourish Research | Chicago, Illinois | United States | |
| DM Clinical Research | Melrose Park, Illinois | United States | |
| Affinity Health Corp | Oak Brook, Illinois | United States | |
| Accellacare - DuPage | Oak Lawn, Illinois | United States | |
| MOC Research | Mishawaka, Indiana | United States | |
| Velocity Clinical Research Valparaiso | Valparaiso, Indiana | United States | |
| University of Iowa | Iowa City, Iowa | United States | |
| Meridian Clinical Research, LLC | Sioux City, Iowa | United States | |
| AMR Clinical | Lexington, Kentucky | United States | |
| Ochsner Clinic Foundation | Kenner, Louisiana | United States | |
| Ochsner Medical Center - Kenner | Kenner, Louisiana | United States | |
| Velocity Clinical Research, Metairie | Metairie, Louisiana | United States | |
| Velocity Clinical Research, Rockville | Rockville, Maryland | United States | |
| ActivMed Practices & Research, LLC | Beverly, Massachusetts | United States | |
| ActivMed Practices & Research, LLC | Methuen, Massachusetts | United States | |
| University of Massachusetts Chan Medical School | Worcester, Massachusetts | United States | |
| Michigan Center of Medical Research (MICHMER) | Farmington Hills, Michigan | United States | |
| Ascension St. John Hospital Vaccine Research Unit | Grosse Pointe Woods, Michigan | United States | |
| Oakland Medical Research | Troy, Michigan | United States | |
| Arcturus Healthcare , PLC, Troy Internal Medicine Research Division | Troy, Michigan | United States | |
| Saint Louis University | St Louis, Missouri | United States | |
| Sundance Clinical Research | St Louis, Missouri | United States | |
| Skyline Medical Center, PC/CCT Research | Elkhorn, Nebraska | United States | |
| Quality Clinical Research | Omaha, Nebraska | United States | |
| Wr-Crcn, Llc. | Las Vegas, Nevada | United States | |
| Alliance for Multispecialty Research, LLC | Las Vegas, Nevada | United States | |
| Las Vegas Clinical Trials | North Las Vegas, Nevada | United States | |
| ActivMed Practices and Research, LLC. | Portsmouth, New Hampshire | United States | |
| South Jersey Infectious Disease | Somers Point, New Jersey | United States | |
| IMA Clinical Research Warren | Warren Township, New Jersey | United States | |
| Velocity Clinical Research, Binghamton | Binghamton, New York | United States |
163 more sites not listed.